Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

BACKGROUND: Targeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator of DDR. We conducted a phase II trial of ceralaser...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Minsuk, Kim, Gahyun, Kim, Ryul, Kim, Kyu-Tae, Kim, Seung Tae, Smith, Simon, Mortimer, Peter G S, Hong, Jung Yong, Loembé, Arsene-Bienvenu, Irurzun-Arana, Itziar, Koulai, Loumpiana, Kim, Kyoung-Mee, Kang, Won Ki, Dean, Emma, Park, Woong-Yang, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258491/
https://www.ncbi.nlm.nih.gov/pubmed/35790315
http://dx.doi.org/10.1136/jitc-2022-005041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258491/
https://www.ncbi.nlm.nih.gov/pubmed/35790315
http://dx.doi.org/10.1136/jitc-2022-005041

Ejemplares similares